Preprint Review Version 1 This version is not peer-reviewed

High-Throughput Direct Mass Spectrometry-Based Metabolomics to Characterize Metabolite Fingerprints Associated with Alzheimer’s Disease Pathogenesis

Version 1 : Received: 23 August 2018 / Approved: 23 August 2018 / Online: 23 August 2018 (10:10:47 CEST)

A peer-reviewed article of this Preprint also exists.

González-Domínguez, R.; Sayago, A.; Fernández-Recamales, Á. High-Throughput Direct Mass Spectrometry-Based Metabolomics to Characterize Metabolite Fingerprints Associated with Alzheimer’s Disease Pathogenesis. Metabolites 2018, 8, 52. González-Domínguez, R.; Sayago, A.; Fernández-Recamales, Á. High-Throughput Direct Mass Spectrometry-Based Metabolomics to Characterize Metabolite Fingerprints Associated with Alzheimer’s Disease Pathogenesis. Metabolites 2018, 8, 52.

Journal reference: Metabolites 2018, 8, 52
DOI: 10.3390/metabo8030052

Abstract

Direct mass spectrometry-based metabolomics has been widely employed in the last years to characterize metabolic alterations underlying to Alzheimer’s disease development and progression. This high-throughput approach presents a great potential for fast and simultaneous fingerprinting of a vast number of metabolites, which can be applied to multiple biological samples such as serum/plasma, urine, cerebrospinal fluid and tissues. In this review article we present the main advantages and drawbacks of metabolomics based on direct mass spectrometry compared with conventional analytical techniques, and provide a comprehensive revision of the literature on the application of these tools in Alzheimer’s disease research.

Subject Areas

metabolomics; direct mass spectrometry; Alzheimer’s disease; pathogenesis; biomarkers

Comments (1)

Comment 1
Received: 24 August 2018
Commenter: Edmond Sanganyado (Click to see Publons profile: )
The commenter has declared there is no conflict of interests.
Comment: In this mini-review the authors discuss the application of direct mass spectrometry in studying Alzheimer's disease. The authors should probably a brief discussion on challenges in direct mass spectrometry, why direct mass spectrometry is used in Alzheimer's disease metabolomics, future research directions, current knowledge gaps, etc. Furthermore, figures and tables could enrich the manuscript, particularly on illustrating the principles of the technique and current practices, respectively.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.